26+ years in the pharmaceutical and biotechnology industry, which includes public and privately held large pharmaceutical, drug delivery, and small biotechnology companies. Held positions focused on research, early development (Ph.I/II)), late development (Ph.III), and business development, which include senior research immunologist, vice president of immunology, and director of business development. Since 2003, major focus has been on research and early stage development of cancer immunotherapeutic small molecules and biologicals.
Since 2003, major focus on early stage development (research, translational, Ph. I/II) of cancer immunotherapeutic small molecules and biologicals, specifically the use of innate immune stimulators (toll-like receptor and c-type lectin ligands) for the purpose of enhancing adaptive immunity and down-regulating immune suppression. More recent focus has been on vaccine adjuvants and on Ph. III drug-device product (manufacturing focus). Scientific focus Immuno-oncology, vaccinology, innate-adaptive immunity interface, dendritic cell and cytotoxic T-cell biology, tumor microenvironment, cancer models for evaluating immunotherapies, pathogen-associated molecular patterns, Toll-like receptor ligands, vaccine adjuvants